MSLE · Satellos Bioscience Inc. · Documents
$6.88
+0.34 (+5.20%)
At close · Oct 27
Return incl. dividend (before tax)
Q2 2026 earnings call transcript
Market Cap
$138.76M
Shares
21.22M
Volume · Oct 27
22.18K
Avg daily vol (3M)
40.9K
The company's filings as submitted to the SEC's EDGAR system — 10-K, 10-Q, 8-K, proxy statements and more — listed most recent first.
| Type | AI summary | Filing Date | Period | Open |
|---|---|---|---|---|
| 6-K | Satellos Bioscience Inc. formed a Scientific Advisory Board to guide research into regeneration, aging and neurodegenerative biology, with Janet Rossant serving as chair. The board will advise on stem cell biology, molecular signaling and disease pathology. | 2026-10-27 | — | |
| 6-K | Satellos Bioscience Inc. management will participate in the Guggenheim 3rd Annual Healthcare Innovation Conference on Nov. 9, 2026 and the Jefferies Global Healthcare Conference on Nov. 18-19, 2026, with investor meetings available during both events. | 2026-10-21 | — | |
| 6-K | Satellos Bioscience Inc. received U.S. Patent No. 12,747,245 covering forazapadin’s composition of matter, providing protection through Sept. 6, 2044. Forazapadin advances in Phase 2 development, with an FSHD Phase 2 clinical study expected to begin in the fourth quarter of 2026. | 2026-10-05 | — | |
| 6-K | Satellos Bioscience Inc. completed BASECAMP enrollment, meeting and surpassing its target in less than nine months; it now expects to report topline forazapadin data in the first quarter of 2027. | 2026-09-30 | — | |
| 6-K | Satellos Bioscience Inc. announced FDA clearance for forazapadin’s IND application in FSHD; FSHD Canada Foundation will provide up to US$5 million over five quarters, supporting a Phase 2 study expected to begin in Q4 2026. | 2026-09-24 | — | |
| Investor Event Transcript | — | 2026-09-16 | 2026-09-30 | |
| 6-K | — | 2026-09-15 | — | |
| 6-K | — | 2026-09-09 | — | |
| 6-K | — | 2026-09-01 | — | |
| 6-K | — | 2026-08-14 | — | |
| 6-K | — | 2026-08-13 | 2026-06-30 | |
| 6-K | — | 2026-07-08 | — | |
| 6-K | — | 2026-06-29 | — | |
| 6-K | — | 2026-06-25 | — | |
| 6-K | — | 2026-06-18 | 2026-06-17 | |
| 6-K | — | 2026-06-17 | — | |
| Investor Event Transcript | — | 2026-06-02 | 2026-06-30 | |
| 6-K | — | 2026-05-27 | — | |
| 6-K | — | 2026-05-20 | 2026-05-19 | |
| 6-K | — | 2026-05-15 | 2026-03-31 | |
| Investor Event Transcript | — | 2026-04-21 | 2026-06-30 | |
| 6-K | — | 2026-04-09 | — | |
| 6-K | — | 2026-03-27 | — | |
| 40-F | — | 2026-03-27 | 2025-12-31 | |
| 6-K | — | 2026-03-10 | — | |
| 6-K | — | 2026-02-24 | — | |
| 6-K | — | 2026-02-19 | — | |
| 6-K | — | 2026-02-18 | — | |
| 6-K | — | 2026-02-17 | — | |
| 6-K | — | 2026-02-12 | 2026-02-10 | |
| 6-K | — | 2026-02-10 | 2026-02-09 | |
| 6-K | — | 2026-02-10 | — | |
| 6-K | — | 2026-02-06 | — |
Showing 1–33 of 33 filings